Ozempic vs Wegovy: The Same Drug With Two Different Jobs

Ozempic and Wegovy are the same molecule: semaglutide, made by the same company, Novo Nordisk. The differences that actually matter are the job the FDA approved each brand for (type 2 diabetes vs chronic weight management), the dose ladder each label allows, and the way insurance treats each indication. If you understand those three things, every confusing headline about these drugs gets simpler.

One molecule, two brands

Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone your body already makes after eating: it slows stomach emptying, blunts appetite signaling in the brain, and improves insulin response when blood sugar is high.

Novo Nordisk sells injectable semaglutide under two names:

• Ozempic, FDA-approved in December 2017 for type 2 diabetes, with cardiovascular risk-reduction language added later.
• Wegovy, FDA-approved in June 2021 for chronic weight management. The FDA's own announcement called it the first new weight-management drug approval since 2014.

Same factory, same molecule, different label on the pen and different paperwork at the FDA.

Why the indication matters more than the name

A drug's indication is the specific use the FDA reviewed evidence for and approved. It controls three practical things:

1. The dose ladder. Ozempic's diabetes label titrates to a maximum of 2 mg weekly. Wegovy's weight-management label climbs to 2.4 mg weekly. In the STEP 1 trial that supported Wegovy's approval, adults without diabetes on 2.4 mg lost about 15% of body weight on average over 68 weeks, versus about 2.4% on placebo.

2. Insurance coverage. Most U.S. health plans treat diabetes drugs and weight-management drugs as separate categories. Plenty of plans that cover Ozempic for diabetes simply exclude weight-loss medication as a class. The result is the strange-but-common situation where the same molecule is covered under one name and denied under the other. That is plan design, not science.

3. Marketing and prescribing. Novo Nordisk can only market each brand for its approved use. Clinicians, however, can legally prescribe off-label, which is why "Ozempic for weight loss" became shorthand in the culture even though weight management is Wegovy's job on paper.

The practical differences at a glance

	Ozempic	Wegovy
Molecule	Semaglutide	Semaglutide
Maker	Novo Nordisk	Novo Nordisk
FDA-approved for	Type 2 diabetes	Chronic weight management
Approved	2017	2021
Max maintenance dose	2 mg weekly	2.4 mg weekly
Typical coverage path	Diabetes benefit	Weight-management benefit (often excluded)

What this means if you are on either one

The molecule does not know which box it shipped in. Side effects, food strategies, and the slow-ramp titration logic are the same conversation for both brands. What changes is the administrative layer around you: prior authorizations, coverage appeals, and which dose your prescription can climb to.

Two things are worth doing regardless of the name on your pen:

Track your response, not the brand discourse. Weight trend, appetite, nausea, energy: your own logged data over weeks is more informative than any headline comparing the two brands, because the brands are the same drug.

Know your indication when you talk to your insurer. If a claim is denied, the denial is almost always about the indication category, not about semaglutide itself. That distinction is the first thing to clarify in an appeal conversation with your plan or your prescriber's office.

The bigger family

Semaglutide also exists as a daily oral tablet (Rybelsus) and now competes with tirzepatide (Mounjaro for diabetes, Zepbound for weight), a dual-hormone cousin made by Eli Lilly with its own pair of brand names split by indication. The same one-molecule-two-jobs logic applies across the whole category, so once you can read Ozempic vs Wegovy, you can read the entire GLP-1 shelf.

If a version of semaglutide you encounter is not one of these FDA-approved brands, it lives in different regulatory territory entirely. We cover that in is compounded semaglutide still legal.